Evidence map›Paper›PMID 31328154›Full record

ArticleScience advances2019

LKB1 specifies neural crest cell fates through pyruvate-alanine cycling.

Anca G Radu, Sakina Torch, Florence Fauvelle, Karin Pernet-Gallay, Anthony Lucas, Renaud Blervaque, Véronique Delmas, Uwe Schlattner, Laurence Lafanechère, Pierre Hainaut and 7 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Loss of Lkb1 cooperates with BrafMolecular oncology · 2025
    Article
  3. PKM2 controls cochlear development through lactate-dependent transcriptional regulation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Anca G RaduInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.ORCID 0000-0002-7495-3037
Sakina TorchInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.ORCID 0000-0003-3691-4376
Florence FauvelleUniv. Grenoble Alpes, INSERM, U1216, Grenoble Institute of Neurosciences GIN, 38000 Grenoble, France.
Karin Pernet-GallayUniv. Grenoble Alpes, INSERM, U1216, Grenoble Institute of Neurosciences GIN, 38000 Grenoble, France.
Anthony LucasInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.
Renaud BlervaqueInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.
Véronique DelmasInstitut Curie, Normal and Pathological Development of Melanocytes, CNRS UMR3347; INSERM U1021; Equipe Labellisée-Ligue Nationale Contre le Cancer, Orsay, France.
Uwe SchlattnerLaboratory of Fundamental and Applied Bioenergetics, Univ Grenoble Alpes, 38185 Grenoble, France.
Laurence LafanechèreInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.ORCID 0000-0002-7902-7630
Pierre HainautInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.
Nicolas TricaudINSERM U1051, Institut des Neurosciences de Montpellier (INM), Université de Montpellier, Montpellier, France.
Véronique PingaultINSERM U1163, Institut Imagine, Paris, France.ORCID 0000-0001-7064-0765
Nadège BondurandINSERM U1163, Institut Imagine, Paris, France.
Nabeel BardeesyCancer Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA.ORCID 0000-0003-3867-0416
Lionel LarueInstitut Curie, Normal and Pathological Development of Melanocytes, CNRS UMR3347; INSERM U1021; Equipe Labellisée-Ligue Nationale Contre le Cancer, Orsay, France.ORCID 0000-0002-2010-6107
Chantal ThibertInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.ORCID 0000-0002-1516-5671
Marc BillaudInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.ORCID 0000-0002-4789-2339
Centre National de la Recherche Scientifique · FRInserm · FRHarvard University · USUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic processes underlying the development of the neural crest, an embryonic population of multipotent migratory cells, are poorly understood. Here, we report that conditional ablation of the

Indexed as

AlanineAMP-Activated Protein KinasesAnimalsCell DifferentiationEnergy MetabolismEnteric Nervous SystemGene SilencingMelanocytesMiceMice, KnockoutMitochondriaNerve DegenerationNeural CrestNeurogliaPeripheral Nervous System DiseasesPhenotypeAlanineAMP-Activated Protein KinasesProtein Serine-Threonine KinasesPyruvic AcidStk11 protein, mouse

Identifiers

PMID31328154
PMCPMC6636984
OpenAlexW2960857704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.